ArticleExperimental hematology2009
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.
Article in Experimental hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis.Annals of hematology · 2024Pooled it
- Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.Blood advances · 2019Pooled it
- Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera.Cancer research and treatment · 2026Article
- Recurrent Stroke with Rapid Development of Intracranial Artery Stenosis and Subsequent Successful Mechanical Thrombectomy in Essential Thrombocythemia.Internal medicine (Tokyo, Japan) · 2024Article
- Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.Current treatment options in oncology · 2023Review
- Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms.EJHaem · 2023Article
- Clinical features and outcomes ofBlood research · 2021Article
- Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.International journal of molecular sciences · 2021Review
- Low-Risk Essential Thrombocythemia: A Comprehensive Review.HemaSphere · 2021Review
- Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study.Frontiers in oncology · 2021Article
- JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020Article
- Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.Journal of thrombosis and thrombolysis · 2018Review
- Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.Current hematologic malignancy reports · 2017Review
- Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Leukemia · 2017Review
- Article
- Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016Article
- JAK2V617F allele burden in patients with myeloproliferative neoplasms carrying Trisomy 9, and its relationship with clinical phenotypes.International journal of hematology · 2016Article
- Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Review
- Advances and challenges in the management of essential thrombocythemia.Therapeutic advances in hematology · 2015Review
- The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms.Journal of clinical medicine research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveA direct comparison of the incidence and risk factors of major thrombosis in essential thrombocythemia (ET) and polycythemia vera (PV) according to their respective JAK2V617F allele burden is the object of this study. MATERIALS AND
methodsWe compared the rate (%/patients/year) of major thrombosis in 867 ET patients (57% JAK2V617F) with that of 415 PV patients (all JAK2V617F) and examined risk factors.
resultsPatients with ET wild-type, ET V617F, and PV showed a rate of thrombosis of 1.4%, 2.1%, and 2.7%/patients/year, respectively. The latter was found to progressively increase according to time of diagnosis. Actuarial probability of arterial and venous thrombosis in the first 5 years of diagnosis was roughly similar in the three groups. While in the subsequent periods, the curves of mutated ET patients diverged from wild-type, and after 10 to 15 years the ET-mutated arm approached PV.
conclusionThese findings support the concept of a continuum between ET JAK2 mutated and PV, not only in reference to the hematological phenotype, but also in terms of vascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.